# A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

> **NCT06005974** · PHASE2 · TERMINATED · sponsor: **Recursion Pharmaceuticals Inc.** · enrollment: 18 (actual)

## Conditions studied

- AXIN1 Gene Mutation
- APC Gene Mutation
- Solid Tumor

## Interventions

- **DRUG:** REC-4881

## Key facts

- **NCT ID:** NCT06005974
- **Lead sponsor:** Recursion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-15
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study was terminated due to sponsor decision. This decision was not related to safety concerns.
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005974, "A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06005974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*